Yifan Pharmaceutical Officially Authorized to Sell and Promote Valcyte® in Mainland China
Recently, the company has obtained the right to sell and promote the original product Valcyte® (general name: Valganciclovir Hydrochloride Tablets) in Chinese Mainland, wherein Valcyte® is indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) and the prevention of CMV infection in solid organ transplantation patients who are at risk of CMV infection. This marks a new journey of product life.
With the extensive and long-term use of immunosuppressants, the chances of infection by various pathogens in solid organ transplantation (SOT) recipients have increased significantly. Cytomegalovirus (CMV) infection is the most common viral infection. As SOT recipients are in an immunosuppressive state, the incidence of CMV infection after surgery is much higher than that of normal people. CMV infection is not only a common infectious complication of SOT recipients, but also an important cause of death, posing a serious threat to the survival and quality of life of patients. The Guidelines for Diagnosis and Treatment of CMV Infection in Solid Organ Transplantation Recipients (2019 Edition) issued by the American Society of Transplantation and the Guidelines for Clinical Diagnosis and Treatment of CMV Infection in Organ Transplantation Recipients (2019 Edition) issued by the Chinese Society of Transplantation both recommend valganciclovir hydrochloride tablets as the preferred drug for universal prevention of adult organ transplant recipients.
Valganciclovir Hydrochloride (trade name: Valcyte®) is a new member to the company's blood tumor product line. A galaxy of classic products, including Valcyte® and the company's existing products, including Compound Realgar Natural Indigo Tablets, Plerixafor Injection, Aclarubicin Hydrochloride for Injection, Vincristine Sulfate for Injection, Melphalan Tablets, Ganciclovir for Injection and Propranolol Hydrochloride Oral Solution, have jointly formed an anti-blood-tumor product line which has been increasingly improved and expanded.
